OHTUVAYRE
PDE NEB
Ensifentrine · Merck Sharp & Dohme (formerly Verona Pharma)
Active Medication & Mechanism
- Ensifentrine PDE3 mg per 2.5 mL unit-dose ampule
First-in-class selective dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4. Raising intracellular cAMP/cGMP produces combined bronchodilator and non-steroidal anti-inflammatory effects.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
3 mg/2.5 mL
1 ampule (3 mg) nebulized twice daily (morning and evening) → 6 mg
FDA Approved
Maintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor. First inhaled agent with a novel COPD mechanism in over 20 years (approved June 26, 2024).
Not Approved
Ohtuvayre is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
3 mg/2.5 mL 1 ampule (3 mg) nebulized twice daily (morning and evening) → 6 mg
COPD FDA Approved
Maintenance treatment of COPD in adults. Administer via a standard jet nebulizer with a mouthpiece connected to an air compressor. First inhaled agent with a novel COPD mechanism in over 20 years (approved June 26, 2024).
Asthma Not Approved
Ohtuvayre is not indicated for asthma.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute symptoms of bronchospasm. Use a SABA.